GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The compan… Read more
GeneDx Holdings Corp. (WGS) - Total Liabilities
Latest total liabilities as of September 2025: $201.64 Million USD
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has total liabilities worth $201.64 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeneDx Holdings Corp. - Total Liabilities Trend (2020–2024)
This chart illustrates how GeneDx Holdings Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GeneDx Holdings Corp. Competitors by Total Liabilities
The table below lists competitors of GeneDx Holdings Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tibet Mineral Development Co Ltd
SHE:000762
|
China | CN¥3.59 Billion |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
China | CN¥1.23 Billion |
|
Dgb Financial
KO:139130
|
Korea | ₩96.18 Trillion |
|
Matterport Inc
NASDAQ:MTTR
|
USA | $146.53 Million |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
China | CN¥3.46 Billion |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
China | CN¥7.08 Billion |
|
Yantai Moon Co Ltd
SHE:000811
|
China | CN¥6.01 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down GeneDx Holdings Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneDx Holdings Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneDx Holdings Corp. (2020–2024)
The table below shows the annual total liabilities of GeneDx Holdings Corp. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $174.13 Million | -8.71% |
| 2023-12-31 | $190.74 Million | -34.58% |
| 2022-12-31 | $291.56 Million | +75.65% |
| 2021-12-31 | $165.99 Million | -32.87% |
| 2020-12-31 | $247.25 Million | -- |